Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects - Concepedia

Concepedia

Publication | Closed Access

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

34

Citations

18

References

2009

Year

Nazar Farid, Joseph A. Jakubowski, Christopher D. Payne, Y. G. Li, Yan Jin, C. Steven Ernest, Kenneth J. Winters, John T. Brandt, Daniel E. Salazar, D. S. Small

Current Medical Research and Opinion

Abstract

Dose adjustment should not be necessary when prasugrel is administered with CYP inducers since formation of prasugrel's active metabolite is not affected by potent enzyme induction with rifampin.

References

	Year	Citations
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe, New England Journal of Medicine	2007	6.7K
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation John T. Brandt, Christopher D. Payne, Stephen D. Wiviott, American Heart Journal ThrombopoiesisThrombosisClopidogrel Loading DosesCardiovascular DiseaseActive Metabolite Formation	2006	568
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Tomas Jernberg, Christopher D. Payne, Kenneth J. Winters, European Heart Journal	2006	535
Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y <sub>12</sub> Antagonist, With Clopidogrel in Percutaneous Coronary Intervention Stephen D. Wiviott, Elliott M. Antman, Kenneth J. Winters, Circulation	2005	379
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently Nazar Farid, Christopher D. Payne, D. S. Small, Clinical Pharmacology & Therapeutics	2007	321
Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel David S. Small, Nagy A. Farid, Christopher D. Payne, The Journal of Clinical Pharmacology ThrombopoiesisMolecular PharmacologyThrombosisPlatelet Aggregation InhibitorsHealthy Subjects	2008	315
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 Jessica Rehmel, James A. Eckstein, Nagy A. Farid, Drug Metabolism and Disposition	2006	263
The <i>in vivo</i> pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties Atsuhiro Sugidachi, Fumitoshi Asai, Taketoshi Ogawa, British Journal of Pharmacology	2000	235
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite Atsuhiro Sugidachi, Taketoshi Ogawa, Atsushi Kurihara, Journal of Thrombosis and Haemostasis Molecular PharmacologyThrombosisEfficient GenerationBiochemistryBlood Platelet	2007	218
The Disposition of Prasugrel, a Novel Thienopyridine, in Humans Nagy A. Farid, Richard L. Smith, Todd A. Gillespie, Drug Metabolism and Disposition	2007	211

Page 1